These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38885690)

  • 41. European Commission activities in eHealth.
    Olsson S; Lymberis A; Whitehouse D
    Int J Circumpolar Health; 2004 Dec; 63(4):310-6. PubMed ID: 15709306
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Implementation of the Nagoya Protocol in the European Union and in Germany.
    Greiber T
    Phytomedicine; 2019 Feb; 53():313-318. PubMed ID: 30392747
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Estimating efficiency of Directive 2011/24/EU cross-border healthcare in member states.
    Ibrahim MD; Hocaoglu MB; Numan B; Daneshvar S
    J Comp Eff Res; 2018 Aug; 7(8):827-834. PubMed ID: 29770704
    [No Abstract]   [Full Text] [Related]  

  • 44. [Legal requirements for health protection from the European viewpoint--uniform regulations or reciprocal recognition of public health norms?].
    Schlüter P
    Zentralbl Hyg Umweltmed; 1996 Dec; 199(2-4):105-18. PubMed ID: 9409912
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmaceutical Manufacturing in the EU and the EU-US Mutual Recognition Agreement.
    Gaspar Ernesto LM; Dias Loureiro RM
    PDA J Pharm Sci Technol; 2020; 74(6):617-626. PubMed ID: 32540862
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Twentieth anniversary of the European Union health mandate: taking stock of perceived achievements, failures and missed opportunities - a qualitative study.
    Rosenkötter N; Clemens T; Sørensen K; Brand H
    BMC Public Health; 2013 Nov; 13():1074. PubMed ID: 24225055
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Animal use in the safety evaluation of chemicals: harmonization and emerging needs.
    Spielmann H
    ILAR J; 2002; 43 Suppl():S11-7. PubMed ID: 12388845
    [TBL] [Abstract][Full Text] [Related]  

  • 48. National Facilitators and Barriers to the Implementation of Incentives for Antibiotic Access and Innovation.
    Årdal C; Lacotte Y; Edwards S; Ploy MC; On Behalf Of The European Union Joint Action On Antimicrobial Resistance And Healthcare-Associated Infections Eu-Jamrai
    Antibiotics (Basel); 2021 Jun; 10(6):. PubMed ID: 34205554
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Drug-resistant tuberculosis in the European Union: opportunities and challenges for control.
    Fears R; Kaufmann S; Ter Meulen V; Zumla A;
    Tuberculosis (Edinb); 2010 May; 90(3):182-7. PubMed ID: 20382566
    [TBL] [Abstract][Full Text] [Related]  

  • 50. European survey on decontamination in mass casualty incidents.
    Domres BD; Rashid A; Grundgeiger J; Gromer S; Kees T; Hecker N; Peter H
    Am J Disaster Med; 2009; 4(3):147-52. PubMed ID: 19739457
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cross-sector cooperation in health-enhancing physical activity policymaking: more potential than achievements?
    Hämäläinen RM; Aro AR; Lau CJ; Rus D; Cori L; Syed AM;
    Health Res Policy Syst; 2016 Apr; 14(1):33. PubMed ID: 27129850
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Organ transplantation and the European Union, 2009-2015 developments.
    Van der Spiegel S; Schröder-Bäck P; Brand H
    Transpl Int; 2020 Jun; 33(6):603-611. PubMed ID: 32097506
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Estimating The Appropriate Size Of Global Pull Incentives For Antibacterial Medicines.
    Outterson K
    Health Aff (Millwood); 2021 Nov; 40(11):1758-1765. PubMed ID: 34724432
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Oral healthcare systems in the extended European union.
    Widström E; Eaton KA
    Oral Health Prev Dent; 2004; 2(3):155-94. PubMed ID: 15641621
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Health policy in the European Union: impact on the Spanish health system].
    Guimarães L; Freire JM
    Cad Saude Publica; 2007; 23 Suppl 2():S143-54. PubMed ID: 17625642
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An overview of Compassionate Use Programs in the European Union member states.
    Balasubramanian G; Morampudi S; Chhabra P; Gowda A; Zomorodi B
    Intractable Rare Dis Res; 2016 Nov; 5(4):244-254. PubMed ID: 27904819
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The European Union, economies and public health: not one without the other.
    Vervoort D; van Daalen KR
    Public Health; 2021 May; 194():1-3. PubMed ID: 33836317
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pandemic legislation in the European Union: Fit for purpose? The need for a systematic comparison of national laws.
    Speakman EM; Burris S; Coker R
    Health Policy; 2017 Oct; 121(10):1021-1024. PubMed ID: 28935231
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Restrictions on import of drugs for personal use within the European single market.
    Mäkinen MM; Rautava PT; Forsström JJ
    Eur J Public Health; 2002 Dec; 12(4):244-8. PubMed ID: 12506498
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries.
    Wilking N; Bucsics A; Kandolf Sekulovic L; Kobelt G; Laslop A; Makaroff L; Roediger A; Zielinski C
    ESMO Open; 2019; 4(6):e000550. PubMed ID: 31798977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.